Pacific Biosciences Of California (PACB) Equity Average (2011 - 2026)

Pacific Biosciences Of California's Equity Average history runs 16 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 98.71% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (down 98.71% YoY), while the FY2025 annual figure was $256.0 million, down 57.62% from the prior year.
• Equity Average was $3.9 million for Q1 2026 at Pacific Biosciences Of California, down from $20.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $762.8 million in Q1 2022 to a low of $3.9 million in Q1 2026.
• Historically, Equity Average has averaged $476.3 million across 5 years, with a median of $594.7 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Equity Average jumped 162.89% in 2022, then plunged 98.71% in 2026.
• A 5-year view of Equity Average shows it stood at $594.7 million in 2022, then advanced by 23.17% to $732.5 million in 2023, then slumped by 34.49% to $479.9 million in 2024, then slumped by 95.68% to $20.7 million in 2025, then plunged by 81.38% to $3.9 million in 2026.
• The last three Equity Average figures came in at $3.9 million (Q1 2026), $20.7 million (Q4 2025), and $48.8 million (Q3 2025), per Business Quant data.